Bausch Health Companies Inc. (BHC)

8,62 +0,06 (+0,70%) Alla chiusura: 04:00PM EDT

Bausch Health Companies Inc.

2150 St. ElzEar Boulevard West
Laval, QC H7L 4A8
Canada
514 744 6792
https://www.bauschhealth.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 20.270

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Thomas J. Appio	CEO & Director	2,74M	N/D	1962
Mr. John S. Barresi	Senior VP, Controller, Chief Accounting Officer & Interim CFO	796,8k	N/D	1973
Ms. Seana Carson	Executive VP & General Counsel	872,65k	N/D	1973
Mr. Mirza Dautbegovic	Senior VP & COO	N/D	N/D	N/D
Mr. Josh Coyle	Senior Vice President of Sales & Salix	N/D	N/D	N/D
Ms. Kathleen Fitzpatrick	Senior VP & Chief HR Officer	N/D	N/D	N/D
Dr. Tage Ramakrishna M.D.	Chief Medical Officer and President of R&D	N/D	N/D	1974
Mr. Jeff Hartness	Executive VP of Market Access, Commercial Operations, Neurology, Generics & Government Affairs	N/D	N/D	N/D
Dr. Graham Jackson	Senior VP & Chief Quality Officer	N/D	N/D	N/D
Mr. Cees Heiman	Senior Vice President of Europe & Canada	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Governance aziendale

L'ISS Governance QualityScore di Bausch Health Companies Inc. al 1 aprile 2024 è 4. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 2; diritti degli azionisti: 3; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.